Champions Oncology, Inc.
    SEC Filings

    |
    |

    All SEC filings by Champions Oncology, Inc. (CSBR) — annual and quarterly reports, current reports, registrations, proxies and ownership forms, updated in real time.

    Financials

    10-KAnnual reportView DiffJul 27, 2026
    10-QQuarterly reportView DiffMar 12, 2026
    10-QQuarterly reportView DiffDec 15, 2025
    10-QQuarterly reportView DiffSep 15, 2025
    10-KAnnual reportView DiffJul 23, 2025
    10-QQuarterly reportView DiffMar 17, 2025
    10-QQuarterly reportView DiffDec 16, 2024
    10-QQuarterly reportView DiffSep 13, 2024
    10-KAnnual reportView DiffJul 19, 2024
    10-QQuarterly reportView DiffMar 14, 2024

    Events

    8-KChampions Oncology Reports Record Annual Revenue of $59 MillionJul 27, 2026
    8-KChampions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology StrategyMar 30, 2026
    8-KChampions Oncology Reports Revenue of $16.6 MillionMar 12, 2026
    8-KChampions Oncology Reports Record Quarterly Service Revenue of $14.9 MillionDec 15, 2025
    8-KSubmission of Matters to a Vote of Security HoldersOct 16, 2025
    8-KChampions Oncology Reports Quarterly Revenue of $14.0 MillionSep 15, 2025
    8-KChampions Oncology Reports Record Annual Revenue of $57 MillionJul 23, 2025
    8-KChampions Oncology Announces Appointment of New CeoJul 21, 2025
    8-KChampions Oncology Reports Record Quarterly Revenue of $17.0 MillionMar 11, 2025
    8-KChampions Oncology Reports Quarterly Revenue of $13.5 MillionDec 11, 2024

    Registrations and Prospectuses

    S-8Registration of securities for employeesOct 30, 2024
    424B4Prospectus supplement with pricing infoJun 10, 2016
    S-1/AIPO registrationView DiffMay 24, 2016
    S-1IPO registrationView DiffApr 26, 2016
    424B3Prospectus supplementOct 15, 2015
    POS AMProspectus update (post-effective amendment)Sep 25, 2015
    8-A12BRegistration of securities on exchangeAug 20, 2015
    424B3Prospectus supplementMay 19, 2015
    S-1IPO registrationMay 11, 2015
    D$14m in Equity / Options, Sold $14m, 11 InvestorsMar 25, 2015

    Proxies

    DEFA14AAnnual Meeting of ShareholdersAug 28, 2026
    DEF 14AAnnual Meeting of ShareholdersView DiffAug 28, 2026
    DEFA14AAdditional proxy soliciting materialsAug 22, 2025
    DEF 14ADefinitive proxyView DiffAug 22, 2025
    DEFA14AAdditional proxy soliciting materialsAug 27, 2024
    DEF 14ADefinitive proxyView DiffAug 27, 2024
    DEFA14AAdditional proxy soliciting materialsAug 28, 2023
    DEF 14ADefinitive proxyView DiffAug 28, 2023
    DEF 14ADefinitive proxyView DiffAug 31, 2022
    DEF 14ADefinitive proxyView DiffAug 29, 2022

    Other

    UPLOADLetter from SECMar 4, 2025
    CORRESPCorrespondence with SECMar 3, 2025
    UPLOADLetter from SECFeb 26, 2025
    EFFECTNotice of effectivenessJun 9, 2016
    CORRESPCorrespondence with SECJun 8, 2016
    CORRESPCorrespondence with SECJun 8, 2016
    CORRESPCorrespondence with SECMay 23, 2016
    UPLOADLetter from SECMay 5, 2016
    EFFECTNotice of effectivenessOct 13, 2015
    EFFECTNotice of effectivenessMay 19, 2015

    Ownership

    4Robert Lawrence BraininJan 30, 2026
    4Robert Lawrence BraininJan 30, 2026
    3Robert Lawrence BraininJan 16, 2026
    4Philip P. BreitfeldNov 7, 2025
    4David SidranskyNov 7, 2025
    4Daniel Newman MendelsonNov 7, 2025
    4Scott R TobinNov 7, 2025
    4Joel AckermanNov 7, 2025
    4Joel AckermanNov 6, 2025
    4Philip P. BreitfeldApr 2, 2025